CCA
KNSA icon

Catalyst Capital Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Catalyst Capital Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-404
Closed -$7K – 491
2018
Q2 		$7K Buy
+404
New +$7.31K ﹤0.01% 403

Other funds holding KNSA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Catalyst Capital Advisors's KNSA Position: Q3 2018 in Review

Catalyst Capital Advisors sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2018, closing a stake of 404 shares — an estimated $7K sold.

Catalyst Capital Advisors first reported a position in KNSA in Q2 2018 and held it in 1 quarter. The position peaked at $7K in Q2 2018. 55 funds tracked by Wall St. Rank hold KNSA as of Q3 2018.

  • Catalyst Capital Advisors reported no remaining Kiniksa Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Catalyst Capital Advisors sold 404 Kiniksa Pharmaceuticals shares in Q3 2018, an estimated $7K.
  • Catalyst Capital Advisors first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Catalyst Capital Advisors's Kiniksa Pharmaceuticals position peaked at $7K in Q2 2018.
  • 55 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2018.

Based on Catalyst Capital Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.